In May 2023, the healthcare industry reported 80 deals worth $16.3 billion compared to the last 12-month average (May 2022 to April 2023) of 79 deals worth $17 billion.
A consortium led by Elliott Investment Management enters into an agreement to acquire Syneos Health Inc, an integrated biopharma solutions organisation for a consideration of approximately $7.1 billion; Advent International Corp and Warburg Pincus LLC to acquire Baxter Biopharma Solutions, a provider of sterile contract manufacturing solutions, for a consideration of approximately $4.25 billion; Swedish Orphan Biovitrum AB through its indirect wholly owned subsidiary, to acquire CTI BioPharma Corp, a commercial biopharma company for a consideration of approximately $1.7 billion were the three major deals that contributed 79.8 per cent of the total deal value during May 2023.
|
Deal Date |
Acquirer (s) |
Target |
Deal Value ($M) |
|
10-May-23 |
Elliott Investment Management (US); Patient Square Capital LP (US); Veritas Capital Limited (US) |
Syneos Health Inc (US) |
7,100.0 |
|
08-May-23 |
Advent International Corp (US); Warburg Pincus LLC (US) |
Baxter Biopharma Solutions (US) |
4,250.0 |
|
10-May-23 |
Swedish Orphan Biovitrum AB (Sweden) |
CTI BioPharma Corp (US) |
1,700.0 |
|
22-May-23 |
Ironwood Pharmaceuticals Inc (US) |
VectivBio Holding AG (Switzerland) |
1,000.0 |
|
15-May-23 |
Healthcare Royalty Management; Sagard Healthcare Royalty Part |
Royalty Interest in HEMGENIX |
400.0 |
VC investments increased by 15.4 per cent in May 2023, compared to May 2022
The healthcare industry reported 125 venture capital (VC) deals worth $2.7 billion in May 2023, compared to the last 12-month average (May 2022 to April 2023) of 138 deals worth $2.6 billion.
|
Deal Date |
Acquirer (s) |
Target |
Deal Value ($M) |
|
24-May-23 |
AyurMaya Capital Management Fu; EcoR1 Capital LLC; EDBI Pte Ltd; Emerson Collective LLC; F2 Ventures Limited (Inactive); Fidelity Management & Research; Invus Group LLC; Itochu Corp; Matrix Capital Management Fund; MPM Capital Management, LLC; Novo Nordisk AS; Redmile Group LLC; Samsara BioCapital LLC; SoftBank Vision Fund 2; Surveyor Capital Ltd; The Lee Family Office; Undisclosed; Vertex Ventures US; Woodline Partners |
ElevateBio LLC (US) |
401.0 |
|
23-May-23 |
F2 Ventures Limited (Inactive); MPM Capital Inc |
ReNAgade Therapeutics Inc (US) |
300.0 |
|
25-May-23 |
5AM Venture Management LLC; Deep Track Capital LP; Franklin Templeton L.L.C.; Frazier Life Sciences; Janus Henderson Investors; Millennium Management LLC; RA Capital Management LP; TCG Crossover; The Column Group LLC; Venrock Healthcare Capital Par; Willett Advisors LLC |
Carmot Therapeutics Inc (US) |
150.0 |
|
09-May-23 |
4BIO Ventures Management Ltd; Abingworth; Ajinomoto Co Inc; Cathay Capital; DCVC Bio; Deerfield Management Co LP; Digitalis Ventures; Petrichor, Inc. |
Ascend Gene & Cell Therapies Ltd (United Kingdom) |
117.5 |
|
16-May-23 |
Leaps by Bayer; Piper Heartland Healthcare Cap; RA Capital Management LP; Sectoral Asset Management Inc |
Boundless Bio Inc (US) |
100.0 |
ElevateBio LLC, a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, raising $401 million in series D round to expand its cell and gene technology platforms; ReNAgade Therapeutics Inc, a developer of Ribonucleic acid (RNA) delivery technologies to unlock inaccessible cells for an array of addressable diseases, raising $300 million on in series A financing to Unlock the Limitless Potential of RNA Medicine; and Carmot Therapeutics Inc., a clinical-stage biotechnology company raising $150 million in series E financing to advance its pipeline of treatments for Obesity and Diabetes, were the three major VC deals reported in May 2023.